20 April 2017

Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology, announces that its notice of Annual General Meeting ("AGM"), including Explanatory Notes and Form of Proxy, has today been posted to shareholders. The AGM will be held at 4.00pm on 14 June 2017 at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

Futura's annual report and accounts for the year ended 31 December 2016 (the "Annual Report") is available to shareholders as an electronic communication pursuant to the Companies Act 2006 and is now available at the Company's website www.futuramedical.com, along with the notice of AGM. Copies of the Annual Report have today been posted to shareholders who have opted out of receiving electronic communications. Shareholders who would like to attend the AGM are invited to contact Buchanan on 020 7466 5000 or email stephaniew@buchanan.uk.com.

 

For further information please contact:

Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com

Nominated Adviser:
N+1 Singer
Aubrey Powell / Liz Yong / Thomas Smale
Tel: +44 (0) 20 7496 3000

For media enquiries please contact:

Buchanan Communications Limited
Mark Court / Sophie Cowles /
Stephanie Watson
Tel: +44 (0) 20 7466 5000

 

Notes to editors:

About Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.com